DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Anifrolumab
Anifrolumab
(CHMP) Agenda for the Meeting on 22-25 February 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Study Protocol
Final Scope PDF 184 KB
Collaborations on Imaging – the Medimmune’S Innovative Way
110 Identification and Treatment of Rheumatologic Diseases
Antibodies to Watch in 2021 Hélène Kaplona and Janice M
(LLDAS) Attainment Discriminates Responders in a Systemic Lupus
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
Regulatory Science Challenges in the Development of Drugs for Systemic Lupus Erythematosus
(INN) for Biological and Biotechnological Substances
246992764-Oa
Outlook for Global Medicines Through 2021 Balancing Cost and Value
Downloaded 19 September 2019 ]
Anifrolumab-Fnia) Injection, for Intravenous Use Risk If Using in Patients with Severe Or Chronic Infections
Read the Full Report (Pdf)
Stembook 2018.Pdf
Top View
Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
(INN) for Biological and Biotechnological Substances
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
String of Successful Trials in SLE: Have We Cracked the Code?
2020 ACR Convergence Study Sponsor Statements
Advances in Lupus Nephritis Pathogenesis: from Bench to Bedside
Spotlight on Anifrolumab and Its Potential for the Treatment of Moderate-To-Severe Systemic Lupus Erythematosus
List of the Compassionate Use Programmes
Positive Results for Anifrolumab in Phase III SLE Trial
Trial of Anifrolumab in Active Systemic Lupus Erythematosus E.F
Interferon Lambda in Inflammation and Autoimmune Rheumatic Diseases
Treatment of Rheumatoid Arthritis with Biological Agents —As a Typical and Common Immune-Mediated Inflammatory Disease
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Backgrounder on Anifrolumab and Type I Interferons
Systemic Lupus Erythematosus Overview
Specialty Pipeline Monthly Update June 2021
Voclosporin in Lupus Nephritis: • Phase II Study Compared High and Low Dose Voclosporin in Combination with Mycophenolate Vs
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Antibodies to Watch in a Pandemic
(INN) for Biological and Biotechnological Substances
(INN-Nimet) 15.6.2020
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate-To-Severe Systemic Lu
Safety, Tolerability and Pharmacokinetics of Subcutaneous and Intravenous Anifrolumab in Healthy Volunteers
Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
Specialty Pipeline MONTHLY UPDATE
2016 Medicines in Development for Autoimmune Diseases